TY - JOUR T1 - Higher hospitalization and mortality rates among SARS-CoV-2 infected Persons in Rural America JF - medRxiv DO - 10.1101/2021.10.05.21264543 SP - 2021.10.05.21264543 AU - Alfred Jerrod Anzalone AU - Ronald Horswell AU - Brian Hendricks AU - San Chu AU - William Hillegass AU - William Beasley AU - Jeremy Harper AU - Clifford Rosen AU - Lucio Miele AU - James McClay AU - Susan L Santangelo AU - Sally Hodder Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264543.abstract N2 - IMPORTANCE Rural communities are among the most underserved and resource-scarce populations in the United States (US), yet there are limited data on COVID-19 mortality in rural America. Furthermore, rural data are rarely centralized, precluding comparability across urban and rural regions.OBJECTIVE The purpose of this study is to assess hospitalization rates and all-cause inpatient mortality among persons with definitive COVID-19 diagnoses residing in rural and urban areas.DESIGN, SETTINGS, AND PARTICIPANTS This retrospective cohort study from the National COVID Cohort Collaborative (N3C) examines a cohort of 573,018 patients from 27 US hospital systems presenting with SARS-CoV-2 infection between January 2020 and March 2021, of whom 117,897 were hospitalized. A sample of 450,725 hospitalized persons without COVID-19 diagnoses was identified for comparison.EXPOSURES ZIP Codes provided by source hospital systems were classified by urban-rural gradient through a crosswalk to the US Department of Agriculture Rural-Urban Commuting Area Codes.MAIN OUTCOMES AND MEASURES Primary outcomes were hospitalization and all-cause mortality among hospitalized patients. Kaplan-Meier analysis and mixed effects logistic regression were used to estimate 30-day survival in hospitalized patients and associations between rurality, hospitalization, and inpatient mortality while controlling for major risk factors.RESULTS Rural patients were more likely to be older, white, have higher body mass index, and diagnosed with SARS-CoV-2 later in the pandemic compared with their urban counterparts. Rural compared with urban inhabitants had higher rates of hospitalization (23% vs. 19%) and all-cause mortality among hospitalized patients (16% vs. 11%). After adjustment for demographic and baseline differences, rural residents (both urban adjacent and non-adjacent) with COVID-19 were more likely to be hospitalized (Adjusted Odds Ratio (AOR) 1.41, 95% Confidence Interval (CI), 1.37-1.45 and AOR 1.42, CI 1.35-1.50) and to die or be transferred to hospice (AOR 1.62, CI 1.30-1.49 and 1.38, CI 1.30-1.49), respectively. Similar differences in mortality were noted for hospitalized patients without SARS-CoV-2 infection.CONCLUSIONS Hospitalization and inpatient mortality are higher among rural compared with urban persons with COVID-19, even after adjusting for several factors, including age and comorbidities. Further research is needed to understand the factors that drive health disparities in rural populations.QUESTION Do mortality and hospitalization rates among rural SARS-CoV-2 infected patients in the United States differ from that of their urban counterparts?FINDINGS Hospitalization and mortality rates were significantly greater among rural compared with urban patients, even after adjusting for rural-urban differences including age and comorbidities. Similarly, in persons without SARS-CoV-2 infection, mortality rates were also higher among rural patients.MEANING These findings demonstrate a pervasive rural-urban discrepancy in all-cause inpatient mortality among rural individuals in the U.S. infected with SARS-COV-2 as well as among those who were uninfected. Further research is needed to understand factors driving health disparities among rural populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project described was supported by the National Institute of General Medical Sciences, U54GM104942-05S2, U54GM115458, U54GM104940, U54GM104938, U54GM115516, U54GM115677, U54GM115428, and U54GM104941. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Institute of Health's (NIH) National COVID Cohort Collaborative (N3C) Data Utilization Request Approval committee approved the data The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The study protocol was reviewed by the N3C Data Access Committee: RP-504BA5. Use of the N3C data for this study is authorized under the following IRB Protocols: -University of Nebraska Medical Center, Omaha, Nebraska: #050-21-EP -Pennington Biomedical Research Center, Baton Rouge, Louisiana: #2021-016-PBRC -Louisiana State University Health Sciences Center, New Orleans, Louisiana: LM #1776 -West Virginia University, Morgantown, West Virginia: #2012192778 -University of Mississippi Medical Center, Jackson, Mississippi: #2020V0280 -Maine Medical Center Research Institute, Scarborough, Maine: #1697848-2 -University of Oklahoman, Norman, Oklahoma: #12947I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this manuscript are available publicly in the National COVID Cohort Collaborative (N3C). Data utilized in this study are from release 32. All code and concepts described herein are available on our project GitHub repository: https://github.com/National-COVID-Cohort-Collaborative/CS-Rural-Health/tree/main/rural-mortality-and-hospitalization https://covid.cd2h.org/ ER -